Omnicom and Achieve Life Sciences Team Up for AI-Driven Launch of Nicotine Dependence Treatment
Omnicom Group Inc. (NYSE: OMC) has been appointed as the agency of record for Achieve Life Sciences Inc. (NASDAQ: ACHV) to lead the US commercial launch of cytisinicline, a potential new treatment for nicotine dependence. This marks the first novel treatment option in nearly 20 years.
The partnership, announced on June 26, builds on an existing relationship and focuses on a technology-led, integrated, and data-driven launch strategy. Credera, Omnicom’s technology division, is developing the US launch platform using AI-enabled marketing tools. These tools have demonstrated success in healthcare and other sectors by enabling precise targeting, optimizing channel performance, and accelerating engagement with healthcare professionals and patients.
A Unified Team for a Cross-Functional Approach
Omnicom has brought together a diverse agency team, drawing on expertise from:
- Goodby, Silverstein & Partners for consumer brand development
- DDB Health for medical education
- Ketchum Health for strategic public relations and communications
This approach leverages insights from various industries to set a new standard for biopharma commercialization, combining creative, educational, and PR strategies with advanced technology.
About the Companies
- Omnicom Group Inc. provides advertising, marketing, and corporate communications services across multiple sectors.
- Achieve Life Sciences Inc. is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence in Canada, the US, and the UK.
For PR and communications professionals, this partnership highlights the increasing role of AI-driven platforms in healthcare launches and the benefits of cross-disciplinary teams combining creativity and technology.
To learn more about AI applications in marketing and communications, check out Complete AI Training’s latest AI courses.
Your membership also unlocks:
